Skip to content
Get in SYNC

*Disclaimer: The cannabinoid potencies of our oils are subject to batch variance (+/- 10%) depending on the natural yield of the plant.

All sales are final. No product returns will be accepted, and no exchanges will be available. Please note that our cut-off for weekday orders for shipping is 11:00 a.m. PST. Prices shown are per gram, and potential THC and CBD numbers are for the decarboxylated product.

SYNC PRODUCT INFORMATION

Fast Action Spray that uses nanoemulsion technology to achieve faster and more predictable effects. The discreet sublingual spray bottle allows for a high degree of control over the dosage. It will be available in both a THC and a CBD format.

 ⇒ Download Nanoemulsion Fact Sheet

Our cannabis oils are whole-plant cannabis extracts that deliver the benefits of active cannabinoids and terpenes orally. Our team of research scientists is working to develop new product lines containing our cannabis extracts, which offer faster onset/offset times and improved consistency and reproducibility, allowing users to better control their experience while enjoying all of the benefits that they are used to with Emerald products. Further, Emerald is committed to using the best ingredients available to support your health and well-being while enjoying cannabis responsibly. New product launches in 2020 will see the introduction of a 100% coconut-derived medium-chain triglycerides as a carrier, as well as naturally flavoured offerings. Check back soon to see what’s new.

LOOKING FOR medical cannabis?

Learn more about Emerald’s medical cannabis products available for registered patients. If you are interested in acquiring a prescription and registering to shop online, follow the simple steps. 

REBECCA WONG

Vice President, Quality and Regulatory Affairs

Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning preclinical, clinical, and commercial phases for pharmaceuticals, genetically engineered products and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she led the strategy for quality assurance, equipment validation, compliance auditing, document management, and GxP training. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

JENN HEPBURN

Chief Financial Officer

Ms. Hepburn brings over a decade of experience in accounting and finance to the team at Emerald Health Therapeutics. She is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held Controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.

AVTAR DHILLON

Executive Chairman

Dr. Dhillon is a life sciences entrepreneur with more than 35 years of experience. As a founder/co-founder or lead investor in dozens of life science companies, he has raised more than $1B in public and private financings. He is currently the Chairman, CEO and President of Emerald Health Sciences, a holding company with a portfolio broadly focused on the development of pharmaceutical, botanical, and nutraceutical products, including a controlling position in Emerald Health Therapeutics. As President and CEO of Inovio Pharmaceuticals, Inc., Dr. Dhillon led a turnaround with multiple successful financings and licensing deals with Merck, Wyeth (now Pfizer) and Roche. Before joining Inovio, he was Vice President of MDS Capital Corp. (now Lumira Capital Corp.). Dr. Dhillon now serves as an active board member and chairman for multiple life science and investment companies, and was previously Chairman of the Cannabis Canada Council. Prior to his business career, Dr. Dhillon practiced family medicine. He has a BSc (Honours) in Human Physiology and an MD from the University of British Columbia.

RIAZ BANDALI

President & Cheif Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and, Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.

RIAZ BANDALI 

President & Chief Executive Officer 

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and, Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.s